Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 7/20 | 0.45 |
| ▸ | MMP9 | P14780 | 7/20 | 0.45 |
| ▸ | MMP3 | P08254 | 2/20 | 0.45 |
| ▸ | MMP8 | P22894 | 5/20 | 0.44 |
| ▸ | MMP13 | P45452 | 5/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11484713 | 0.98 | MMP2 (0.47) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL11534423 | 0.98 | MMP2 (0.47) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL10407006 | 0.98 | MMP2 (0.47) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL6331007 | 0.94 | TDP1 (0.40) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL11167483 | 0.92 | MMP2 (0.42) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL11534742 | 0.90 | MMP2 (0.45) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL6695687 | 0.90 | PDE7A (0.41) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL6692266 | 0.86 | LMNA (0.40) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL2138557 | 0.85 | PDE7A (0.46) | MMP2MMP9MMP3TDP1CYP19A1 | |
| SCHEMBL28264380 | 0.83 | MMP2 (0.43) | MMP2MMP9MMP3MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 350 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197701-A1 | ANDROGEN RECEPTOR INHIBITION TO TREAT SEPSIS AND SHOCK | APPLIED BIOLOGY, INC. | 2024-06-20 | — | — | US | claimed |
| US-20220186227-A1 | Therapeutic Targets for Oncogenic KRAS-Dependent Cancers | UNIVERSITY OF MASSACHUSETTS | 2022-06-16 | — | — | US | claimed |
| EP-3946629-A1 | THERAPEUTIC TARGETS FOR ONCOGENIC KRAS-DEPENDENT CANCERS | University Of Massachusetts (US) | 2022-02-09 | — | — | EP | claimed |
| WO-2020198488-A1 | THERAPEUTIC TARGETS FOR ONCOGENIC KRAS-DEPENDENT CANCERS | UNIVERSITY OF MASSACHUSETTS (US) | 2020-10-01 | — | — | WO | claimed |
| CN-108658869-A | Compound with anti-tumor activity and preparation method thereof and the purposes in pharmacy | 复旦大学 | 2018-10-16 | — | — | CN | claimed |
| EP-3329775-A1 | PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | Medivation Prostate Therapeutics LLC (US) | 2018-06-06 | — | — | EP | claimed |
| US-9174943-B2 | Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2015-11-03 | — | — | US | claimed |
| CN-103108549-B | Method for synthesizing diarylthiohydantoin and diarylhydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2015-09-09 | — | — | CN | claimed |
| WO-2015042170-A1 | COMPOSITIONS AND USES OF COMBINATIONS OF DIM-RELATED INDOLES AND SELECTED ANTI-ANDROGEN COMPOUNDS | WAYNE STATE UNIVERSITY (US) | 2015-03-26 | — | — | WO | claimed |
| CN-104341396-A | Diaryl hydantoin derivative, as well as preparation method, medicine composition and application thereof | SHANGHAI PHARMACEUTICALS HOLDING CO LTD | 2015-02-11 | — | — | CN | claimed |
| EP-2646553-A1 | COMPOSITIONS AND METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS | Santaris Pharma A/S (DK) | 2013-10-09 | — | — | EP | claimed |
| US-20130190507-A1 | PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS LLC | 2013-07-25 | — | — | US | claimed |
| CN-103108549-A | Method for synthesizing diarylthiohydantoin and diarylhydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS INC | 2013-05-15 | — | — | CN | claimed |
| EP-2538785-A1 | PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | Medivation Prostate Therapeutics, Inc. (US) | 2013-01-02 | — | — | EP | claimed |
| WO-2012065051-A1 | COMPOSITIONS AND METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS | ENZON PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | claimed |
| WO-2011106570-A1 | PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2011-09-01 | — | — | WO | claimed |
| EP-0232311-B1 | TOPICAL COMPOSITION AND METHOD FOR STIMULATING HAIR GROWTH | PROCTOR, Peter H. (US) | 1993-05-12 | — | — | EP | claimed |
| EP-0192660-B1 | ABSORPTION ENHANCING AGENTS | SURVIVAL TECHNOLOGY, INC. (US) | 1992-11-19 | — | — | EP | claimed |
| WO-1988005653-A1 | TOPICAL COMPOSITION FOR STIMULATING HAIR GROWTH WITH STABLE FREE RADICALS | PROCTOR PETER H (US) | 1988-08-11 | — | — | WO | claimed |
| US-20240197701-A1 | ANDROGEN RECEPTOR INHIBITION TO TREAT SEPSIS AND SHOCK | APPLIED BIOLOGY, INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240197701-A1 | ANDROGEN RECEPTOR INHIBITION TO TREAT SEPSIS AND SHOCK | APPLIED BIOLOGY, INC. | 2024-06-20 | — | — | US | disclosed |
| US-11992531-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-20240132452-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-25 | — | — | US | disclosed |
| US-20240132452-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2023239750-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| CN-116723839-A | Tricyclic heterobifunctional compounds for degrading target proteins | C4医药公司 | 2023-09-08 | — | — | CN | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| EP-4228625-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 Therapeutics, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3717457-B1 | PROCESS FOR PREPARATION OF ENZALUTAMIDE USING NOVEL INTERMEDIATE | AARTI INDUSTRIES LTD (IN) | 2023-06-21 | — | — | EP | disclosed |
| JP-2023075313-A | diarylhydantoin compounds | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 2023-05-30 | — | — | JP | disclosed |
| JP-2023075313-A | diarylhydantoin compounds | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 2023-05-30 | — | — | JP | disclosed |
| CN-116003328-A | Diaryl hydantoin compounds | 加利福尼亚大学董事会 | 2023-04-25 | — | — | CN | disclosed |
| US-20230109968-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230109968-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230095223-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| EP-4155403-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | Ionis Pharmaceuticals, Inc. (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| CN-110003114-B | Diarylhydantoin compounds | 加利福尼亚大学董事会 | 2023-01-17 | — | — | CN | disclosed |
| CN-110003114-B | Diarylhydantoin compounds | 加利福尼亚大学董事会 | 2023-01-17 | — | — | CN | disclosed |
| CN-110003114-B | Diarylhydantoin compounds | 加利福尼亚大学董事会 | 2023-01-17 | — | — | CN | disclosed |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20220186227-A1 | Therapeutic Targets for Oncogenic KRAS-Dependent Cancers | UNIVERSITY OF MASSACHUSETTS | 2022-06-16 | — | — | US | disclosed |
| WO-2022081928-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-11292782-B2 | Diarylhydantoin compounds and methods of use thereof | NUVATION BIO INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-11292782-B2 | Diarylhydantoin compounds and methods of use thereof | NUVATION BIO INC. (US) | 2022-04-05 | — | — | US | disclosed |
| CN-108300718-B | Modulation of androgen receptor expression | 苏州瑞博生物技术股份有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-114058617-A | Conjugated antisense compounds and uses thereof | IONIS制药公司 | 2022-02-18 | — | — | CN | disclosed |
| EP-3946629-A1 | THERAPEUTIC TARGETS FOR ONCOGENIC KRAS-DEPENDENT CANCERS | University Of Massachusetts (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-108064162-B | Conjugated antisense compounds and uses thereof | IONIS制药公司 | 2021-12-03 | — | — | CN | disclosed |
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| EP-3897631-A1 | TARGETED PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3886853-A1 | DIARYLHYDANTOIN COMPOUNDS AND METHODS OF USE THEREOF | Nuvation Bio Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| CN-105873917-B | Non-steroidal antiandrogens and selective androgen receptor modulators containing a pyridyl moiety | 恩多研究公司 | 2021-08-10 | — | — | CN | disclosed |
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-05 | — | — | US | disclosed |
| EP-3329775-B1 | PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS LLC (US) | 2021-04-21 | — | — | EP | disclosed |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| EP-3791724-A1 | TREATMENT OF BREAST CANCER | Medivation Prostate Therapeutics LLC (US) | 2021-03-17 | — | — | EP | disclosed |
| US-20210069154-A1 | Treatment of Breast Cancer | MEDIVATION PROSTATE THERAPEUTICS LLC | 2021-03-11 | — | — | US | disclosed |
| US-RE48461-E1 | Modulation of androgen receptor expression | lonis Pharmaceuticals, Inc. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20210054017-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | IONIS PHARMACEUTICALS INC (US) | 2021-02-25 | — | — | US | disclosed |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10844379-B2 | Conjugated antisense compounds and their use | IONIS PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| EP-3717457-A1 | PROCESS FOR PREPARATION OF ENZALUTAMIDE USING NOVEL INTERMEDIATE | Aarti Industries Limited (IN) | 2020-10-07 | — | — | EP | disclosed |
| WO-2020198488-A1 | THERAPEUTIC TARGETS FOR ONCOGENIC KRAS-DEPENDENT CANCERS | UNIVERSITY OF MASSACHUSETTS (US) | 2020-10-01 | — | — | WO | disclosed |
| EP-3710002-A2 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| CN-111386257-A | Process for preparing enzalutamide using novel intermediates | 阿尔第实业有限公司 | 2020-07-07 | — | — | CN | disclosed |
| WO-2020132561-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200199098-A1 | DIARYLHYDANTOIN COMPOUNDS AND METHODS OF USE THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-06-25 | — | — | US | disclosed |
| WO-2020113088-A1 | DIARYLHYDANTOIN COMPOUNDS AND METHODS OF USE THEREOF | NUVATION BIO INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20200157548-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2020-05-21 | — | — | US | disclosed |
| US-10646575-B2 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-05-07 | — | — | US | disclosed |
| EP-3641762-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2020-04-29 | — | — | EP | disclosed |
| US-10626091-B2 | Process for the preparation of enzalutamide | LAURUS LABS LIMITED (IN) | 2020-04-21 | — | — | US | disclosed |
| US-20200079741-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-03-12 | — | — | US | disclosed |
| US-20200079741-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-03-12 | — | — | US | disclosed |
| US-10570169-B2 | Conjugated antisense compounds and their use | IONIS PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| EP-3610731-A1 | TREATMENT OF BREAST CANCER | Medivation Prostate Therapeutics LLC (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-3546579-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | Ionis Pharmaceuticals, Inc. (US) | 2019-10-02 | — | — | EP | disclosed |
| US-20190262315-A1 | Treatment of Breast Cancer | MEDIVATION PROSTATE THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| CN-110003114-A | Diarylhydantoin compounds | 加利福尼亚大学董事会 | 2019-07-12 | — | — | CN | disclosed |
| CN-110003114-A | Diarylhydantoin compounds | 加利福尼亚大学董事会 | 2019-07-12 | — | — | CN | disclosed |
| CN-110003114-A | Diarylhydantoin compounds | 加利福尼亚大学董事会 | 2019-07-12 | — | — | CN | disclosed |
| US-20190210974-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-11 | — | — | US | disclosed |
| US-20190210974-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-11 | — | — | US | disclosed |
| CN-109790143-A | Amine-linked C for target protein degradation3-glutarimide solution stator body | C4医药公司 | 2019-05-21 | — | — | CN | disclosed |
| US-20190127332-A1 | PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | LAURUS LABS LIMITED (IN) | 2019-05-02 | — | — | US | disclosed |
| CN-105037273-B | Diarylhydantoin compounds | 加利福尼亚大学董事会 | 2019-04-19 | — | — | CN | disclosed |
| CN-105037273-B | Diarylhydantoin compounds | 加利福尼亚大学董事会 | 2019-04-19 | — | — | CN | disclosed |
| CN-105037273-B | Diarylhydantoin compounds | 加利福尼亚大学董事会 | 2019-04-19 | — | — | CN | disclosed |
| CN-109641874-A | C for target protein degradation3The glutarimide degron body of carbon connection | C4医药公司 | 2019-04-16 | — | — | CN | disclosed |
| CN-109562113-A | Spirocyclo-rongeur for target protein degradation | C4医药公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109562107-A | Heterocyclic degrading ligand for target protein degradation | C4医药公司 | 2019-04-02 | — | — | CN | disclosed |
| EP-3454862-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| EP-3454856-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| EP-3455219-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| EP-3455218-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20190076541-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-20190076542-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-20190076540-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| EP-2991661-B1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | IONIS PHARMACEUTICALS INC (US) | 2019-03-13 | — | — | EP | disclosed |
| EP-3430907-A1 | TREATMENT OF BREAST CANCER | Medivation Prostate Therapeutics LLC (US) | 2019-01-23 | — | — | EP | disclosed |
| WO-2018237026-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2018-12-27 | — | — | WO | disclosed |
| EP-2906226-B1 | MODULATION OF ANDROGEN RECEPTOR EXPRESSION | IONIS PHARMACEUTICALS INC (US) | 2018-11-21 | — | — | EP | disclosed |
| US-10131636-B2 | Process for the preparation of Enzalutamide | LAURUS LABS LIMITED (IN) | 2018-11-20 | — | — | US | disclosed |
| US-10111861-B2 | Treatment of breast cancer | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| CN-108658869-A | Compound with anti-tumor activity and preparation method thereof and the purposes in pharmacy | 复旦大学 | 2018-10-16 | — | — | CN | disclosed |
| CN-108658869-A | Compound with anti-tumor activity and preparation method thereof and the purposes in pharmacy | 复旦大学 | 2018-10-16 | — | — | CN | disclosed |
| US-20180245084-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2018-08-30 | — | — | US | disclosed |
| EP-2739153-B1 | TREATMENT OF BREAST CANCER | MEDIVATION PROSTATE THERAPEUTICS LLC (US) | 2018-08-22 | — | — | EP | disclosed |
| CN-108300718-A | The adjusting of expression of androgen receptor | IONIS制药公司 | 2018-07-20 | — | — | CN | disclosed |
| EP-3329775-A1 | PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | Medivation Prostate Therapeutics LLC (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-3329775-A1 | PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | Medivation Prostate Therapeutics LLC (US) | 2018-06-06 | — | — | EP | disclosed |
| CN-108064162-A | Conjugated antisense compounds and uses thereof | IONIS制药公司 | 2018-05-22 | — | — | CN | disclosed |
| US-20180086718-A1 | Diarylhydantoin Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086718-A1 | Diarylhydantoin Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086718-A1 | Diarylhydantoin Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-29 | — | — | US | disclosed |
| CN-104703610-B | modulation of androgen receptor expression | 苏州瑞博生物技术有限公司 | 2018-03-23 | — | — | CN | disclosed |
| EP-2538785-B1 | PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS LLC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-9896437-B2 | Diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-02-20 | — | — | US | disclosed |
| US-9896437-B2 | Diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-02-20 | — | — | US | disclosed |
| US-9896437-B2 | Diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-02-20 | — | — | US | disclosed |
| CN-104341351-B | A kind of Diarylthiohydantoin derivative and its application | 北京海美源医药科技有限公司 | 2018-02-06 | — | — | CN | disclosed |
| WO-2018007624-A1 | ENZALUTAMIDE DERIVATIVES FOR THE TREATMENT OF PROSTATE AND BREAST CANCER | ACTAVIS GROUP PTC EHF (IS) | 2018-01-11 | — | — | WO | disclosed |
| US-20170355727-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | IONIS PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | US | disclosed |
| WO-2017197051-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017197046-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017197036-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017197055-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| US-20170313662-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | LAURUS LABS LIMITED (IN) | 2017-11-02 | — | — | US | disclosed |
| US-9682960-B2 | Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety | ENDORECHERCHE, INC. (CA) | 2017-06-20 | — | — | US | disclosed |
| US-20170158643-A1 | PROCESS FOR PREPARATION OF ANDROGEN RECEPTOR ANTAGONIST | CADILA HEALTHCARE LIMITED (IN) | 2017-06-08 | — | — | US | disclosed |
| US-20170145424-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| EP-3151839-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | Ionis Pharmaceuticals, Inc. (US) | 2017-04-12 | — | — | EP | disclosed |
| US-9611225-B2 | Process for preparation of androgen receptor antagonist | CADILA HEALTHCARE LIMITED (IN) | 2017-04-04 | — | — | US | disclosed |
| US-20170087132-A1 | Treatment of Breast Cancer | MEDIVATION PROSTATE THERAPEUTICS LLC | 2017-03-30 | — | — | US | disclosed |
| US-9567588-B2 | Modulation of androgen receptor expression | IONIS PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| EP-3106162-A1 | DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER | The Regents of the University of California (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-3106162-A1 | DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER | The Regents of the University of California (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9517229-B2 | Treatment of breast cancer | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| EP-3083590-A1 | NON-STEROIDAL ANTIANDROGENS AND SELECTIVE ANDROGEN RECEPTOR MODULATORS WITH A PYRIDYL MOIETY | Endorecherche, Inc. (CA) | 2016-10-26 | — | — | EP | disclosed |
| CN-103997894-B | The treatment of breast carcinoma | 麦迪韦逊前列腺治疗股份有限公司 | 2016-08-24 | — | — | CN | disclosed |
| CN-105873917-A | Non-steroidal antiandrogens and selective androgen receptor modulators with pyridyl moiety | 恩多研究公司 | 2016-08-17 | — | — | CN | disclosed |
| CN-103804358-B | One class Diarylhydantoin derivant, its preparation method, pharmaceutical composition and application | 上海医药集团股份有限公司 | 2016-06-29 | — | — | CN | disclosed |
| CN-103804358-B | One class Diarylhydantoin derivant, its preparation method, pharmaceutical composition and application | 上海医药集团股份有限公司 | 2016-06-29 | — | — | CN | disclosed |
| EP-3020706-A1 | DIARYLTHIOHYDANTOIN COMPOUNDS USEFUL FOR THE TREATMENT OF A HYPERPROLIFERATIVE DISORDER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-2683694-B1 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF | SUZHOU KINTOR PHARMACEUTICALS INC (CN) | 2016-04-27 | — | — | EP | disclosed |
| WO-2016051423-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | LAURUS LABS PRIVATE LIMITED (IN) | 2016-04-07 | — | — | WO | disclosed |
| US-20160068846-A1 | MODULATION OF ANDROGEN RECEPTOR EXPRESSION | ISIS PHARMACEUTICALS INC. (US) | 2016-03-10 | — | — | US | disclosed |
| EP-2991661-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | Ionis Pharmaceuticals, Inc. (US) | 2016-03-09 | — | — | EP | disclosed |
| US-20160017323-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| WO-2015089634-A9 | NON-STEROIDAL ANTIANDROGENS AND SELECTIVE ANDROGEN RECEPTOR MODULATORS WITH A PYRIDYL MOIETY | ENDORECHERCHE, INC. (CA) | 2016-01-14 | — | — | WO | disclosed |
| WO-2015188194-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015179693-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| CN-105037273-A | Diaryl hydantoin compound | UNIV CALIFORNIA | 2015-11-11 | — | — | CN | disclosed |
| US-9181549-B2 | Conjugated antisense compounds and their use | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9175291-B2 | Modulation of androgen receptor expression | ISIS PHARMACEUTICALS INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174943-B2 | Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174943-B2 | Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174943-B2 | Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9139565-B2 | Histone deacetylase (HDAC) inhibitors targeting prostate tumors and methods of making and using thereof | GEORGIA TECH RESEARCH CORPORATION (US) | 2015-09-22 | — | — | US | disclosed |
| CN-103108549-B | Method for synthesizing diarylthiohydantoin and diarylhydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2015-09-09 | — | — | CN | disclosed |
| CN-103108549-B | Method for synthesizing diarylthiohydantoin and diarylhydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2015-09-09 | — | — | CN | disclosed |
| CN-103108549-B | Method for synthesizing diarylthiohydantoin and diarylhydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2015-09-09 | — | — | CN | disclosed |
| US-9126941-B2 | Treatment of hyperproliferative disorders with diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-09-08 | — | — | US | disclosed |
| US-9126941-B2 | Treatment of hyperproliferative disorders with diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-09-08 | — | — | US | disclosed |
| US-9127276-B2 | Conjugated antisense compounds and their use | ISIS PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-9126941-B2 | Treatment of hyperproliferative disorders with diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-09-08 | — | — | US | disclosed |
| EP-2906226-A2 | MODULATION OF ANDROGEN RECEPTOR EXPRESSION | Isis Pharmaceuticals, Inc. (US) | 2015-08-19 | — | — | EP | disclosed |
| US-20150210649-A1 | PROCESS FOR PREPARATION OF ANDROGEN RECEPTOR ANTAGONIST | ZYDUS LIFESCIENCES LIMITED (IN) | 2015-07-30 | — | — | US | disclosed |
| EP-1893196-B2 | DIARYLHYDANTOIN COMPOUND | UNIV CALIFORNIA (US) | 2015-07-29 | — | — | EP | disclosed |
| WO-2015089634-A1 | NON-STEROIDAL ANTIANDROGENS AND SELECTIVE ANDROGEN RECEPTOR MODULATORS WITH A PYRIDYL MOIETY | ENDORECHERCHE, INC. (CA) | 2015-06-25 | — | — | WO | disclosed |
| US-20150175576-A1 | NON-STEROIDAL ANTIANDROGENS AND SELECTIVE ANDROGEN RECEPTOR MODULATORS WITH A PYRIDYL MOIETY | ENDORECHERCHE, INC. (CA) | 2015-06-25 | — | — | US | disclosed |
| CN-104703610-A | Modulation of androgen receptor expression | ISIS PHARMACEUTICALS INC | 2015-06-10 | — | — | CN | disclosed |
| US-20150126718-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-9023879-B2 | Specific diarylhydantoin and diarylthiohydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9023879-B2 | Specific diarylhydantoin and diarylthiohydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9023879-B2 | Specific diarylhydantoin and diarylthiohydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150112082-A1 | DIARYLHYDANTOIN COMPOUNDS | HOWARD HUGHES MEDICAL INSTITUTE | 2015-04-23 | — | — | US | disclosed |
| US-20150112082-A1 | DIARYLHYDANTOIN COMPOUNDS | HOWARD HUGHES MEDICAL INSTITUTE | 2015-04-23 | — | — | US | disclosed |
| WO-2015042170-A1 | COMPOSITIONS AND USES OF COMBINATIONS OF DIM-RELATED INDOLES AND SELECTED ANTI-ANDROGEN COMPOUNDS | WAYNE STATE UNIVERSITY (US) | 2015-03-26 | — | — | WO | disclosed |
| EP-2444085-B1 | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer | UNIV CALIFORNIA (US) | 2015-03-18 | — | — | EP | disclosed |
| EP-2444085-B1 | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer | UNIV CALIFORNIA (US) | 2015-03-18 | — | — | EP | disclosed |
| US-20150065546-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065546-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-05 | — | — | US | disclosed |
| WO-2015018356-A1 | DIARYLHYDANTOIN DERIVATIVE, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | 上海医药集团股份有限公司 (CN) | 2015-02-12 | — | — | WO | disclosed |
| CN-104341396-A | Diaryl hydantoin derivative, as well as preparation method, medicine composition and application thereof | SHANGHAI PHARMACEUTICALS HOLDING CO LTD | 2015-02-11 | — | — | CN | disclosed |
| CN-104341352-A | Diaryl hydantoin compound as androgen receptor antagonist and applications of diaryl hydantoin compound | NANJING HENGJIE BIOTECHNOLOGY CO LTD | 2015-02-11 | — | — | CN | disclosed |
| CN-104341351-A | Novel diarylthiohydantoin derivative and its application | BEIJING HOPE INTERNAT PHARMACEUTICAL TECHNOLOGY DEV CO LTD | 2015-02-11 | — | — | CN | disclosed |
| EP-2397469-B1 | Diarylhydantoin compounds | UNIV CALIFORNIA (US) | 2014-12-31 | — | — | EP | disclosed |
| EP-2397469-B1 | Diarylhydantoin compounds | UNIV CALIFORNIA (US) | 2014-12-31 | — | — | EP | disclosed |
| EP-2400847-B1 | SPECIFIC DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS INC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-20140343111-A1 | DIARYLTHIOHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140343123-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| WO-2014179620-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| EP-2013187-B1 | DIARYLTHIOHYDANTOIN COMPOUNDS | UNIV CALIFORNIA (US) | 2014-10-29 | — | — | EP | disclosed |
| US-20140296312-A1 | TREATMENT OF BREAST CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2014-10-02 | — | — | US | disclosed |
| CN-102755318-B | Hyperproliferative disorders with diarylhydantoin compounds | UNIV CALIFORNIA | 2014-09-10 | — | — | CN | disclosed |
| CN-102755318-B | Hyperproliferative disorders with diarylhydantoin compounds | UNIV CALIFORNIA | 2014-09-10 | — | — | CN | disclosed |
| EP-2739153-A1 | TREATMENT OF BREAST CANCER | Medivation Prostate Therapeutics, Inc. (US) | 2014-06-11 | — | — | EP | disclosed |
| CN-103804358-A | Biaryl hydantoin derivate and preparation method, medicine composition and application thereof | SHANGHAI PHARMACEUTICAL GROUP CO LTD | 2014-05-21 | — | — | CN | disclosed |
| US-8710086-B2 | Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710086-B2 | Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710086-B2 | Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8680291-B2 | Diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680291-B2 | Diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680291-B2 | Diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-03-25 | — | — | US | disclosed |
| US-8658681-B2 | — | — | 2014-02-25 | — | — | US | disclosed |
| US-8658681-B2 | — | — | 2014-02-25 | — | — | US | disclosed |
| US-8658681-B2 | — | — | 2014-02-25 | — | — | US | disclosed |
| US-8648105-B2 | Diarylthiohydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-11 | — | — | US | disclosed |
| US-20140031409-A1 | METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS | SANTARIS PHARMA A/S (DK) | 2014-01-30 | — | — | US | disclosed |
| EP-2620432-A3 | Diarylhydantoin compounds | The Regents Of the University of California (US) | 2013-12-18 | — | — | EP | disclosed |
| EP-2620432-A3 | Diarylhydantoin compounds | The Regents Of the University of California (US) | 2013-12-18 | — | — | EP | disclosed |
| US-20130331421-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2013-12-12 | — | — | US | disclosed |
| US-20130331421-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2013-12-12 | — | — | US | disclosed |
| US-20130289085-A1 | HISTONE DEACETYLASE (HDAC) INHIBITORS TARGETING PROSTATE TUMORS AND METHODS OF MAKING AND USING THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-10-31 | — | — | US | disclosed |
| EP-2646553-A1 | COMPOSITIONS AND METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS | Santaris Pharma A/S (DK) | 2013-10-09 | — | — | EP | disclosed |
| US-8524755-B2 | Specific diarylhydantoin and diarylthiohydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524755-B2 | Specific diarylhydantoin and diarylthiohydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524755-B2 | Specific diarylhydantoin and diarylthiohydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| EP-2620432-A2 | Diarylhydantoin compounds | The Regents Of the University of California (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2620432-A2 | Diarylhydantoin compounds | The Regents Of the University of California (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2620432-A2 | Diarylhydantoin compounds | The Regents Of the University of California (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20130190507-A1 | PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS LLC | 2013-07-25 | — | — | US | disclosed |
| US-20130190507-A1 | PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS LLC | 2013-07-25 | — | — | US | disclosed |
| WO-2013066440-A9 | TREATMENT OF BREAST CANCER | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2013-07-18 | — | — | WO | disclosed |
| US-8450290-B2 | Methods for treating androgen receptor dependent disorders including cancers | ENZON PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| CN-103108549-A | Method for synthesizing diarylthiohydantoin and diarylhydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS INC | 2013-05-15 | — | — | CN | disclosed |
| CN-103108549-A | Method for synthesizing diarylthiohydantoin and diarylhydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS INC | 2013-05-15 | — | — | CN | disclosed |
| CN-103108549-A | Method for synthesizing diarylthiohydantoin and diarylhydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS INC | 2013-05-15 | — | — | CN | disclosed |
| WO-2013066440-A1 | TREATMENT OF BREAST CANCER | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067142-A1 | COMPOUNDS AND TREATMENT METHODS | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067131-A1 | TREATMENT METHODS | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067151-A1 | TREATMENT METHODS USING DIARYLTHIOHYDANTOIN DERIVATIVES | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| EP-2561871-A1 | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer | The Regents of The University of California (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2561871-A1 | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer | The Regents of The University of California (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2561871-A1 | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer | The Regents of The University of California (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20130034501-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130034501-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-07 | — | — | US | disclosed |
| EP-2538785-A1 | PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | Medivation Prostate Therapeutics, Inc. (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-2538785-A1 | PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | Medivation Prostate Therapeutics, Inc. (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120295944-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295944-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-22 | — | — | US | disclosed |
| CN-102755318-A | Hyperproliferative disorders with diarylhydantoin compounds | UNIV CALIFORNIA | 2012-10-31 | — | — | CN | disclosed |
| CN-102755318-A | Hyperproliferative disorders with diarylhydantoin compounds | UNIV CALIFORNIA | 2012-10-31 | — | — | CN | disclosed |
| US-20120251551-A1 | Substituted (Heteroarylmethyl)thiohydantoins | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | US | disclosed |
| CN-101460467-B | Diarylthiohydantoin compounds | UNIV CALIFORNIA | 2012-09-19 | — | — | CN | disclosed |
| CN-102639523-A | Substituted (heteroarylmethyl) thiohydantoin useful as anticancer agents | BAYER SCHERING PHARMA AG | 2012-08-15 | — | — | CN | disclosed |
| EP-2400847-A4 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS INC (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20120190718-A1 | DIARYLTHIOHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120184580-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184580-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2475653-A1 | SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS | Bayer Pharma Aktiengesellschaft (DE) | 2012-07-18 | — | — | EP | disclosed |
| CN-102584712-A | Diarylhydantoin compounds | UNIV CALIFORNIA | 2012-07-18 | — | — | CN | disclosed |
| CN-102584712-A | Diarylhydantoin compounds | UNIV CALIFORNIA | 2012-07-18 | — | — | CN | disclosed |
| CN-102584712-A | Diarylhydantoin compounds | UNIV CALIFORNIA | 2012-07-18 | — | — | CN | disclosed |
| US-8183274-B2 | Treatment of hyperproliferative disorders with diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183274-B2 | Treatment of hyperproliferative disorders with diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183274-B2 | Treatment of hyperproliferative disorders with diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| WO-2012065051-A1 | COMPOSITIONS AND METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS | ENZON PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| EP-2444085-A1 | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer | The Regents of The University of California (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2444085-A1 | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer | The Regents of The University of California (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2444085-A1 | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer | The Regents of The University of California (US) | 2012-04-25 | — | — | EP | disclosed |
| WO-2012050868-A1 | HISTONE DEACETYLASE (HDAC) INHIBITORS TARGETING PROSTATE TUMORS AND METHODS OF MAKING AND USING THEREOF | GEORGIA TECH RESEARCH CORPORATION (US) | 2012-04-19 | — | — | WO | disclosed |
| CN-102421291-A | Specific diarylhydantoin and diarylthiohydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS INC | 2012-04-18 | — | — | CN | disclosed |
| CN-102421291-A | Specific diarylhydantoin and diarylthiohydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS INC | 2012-04-18 | — | — | CN | disclosed |
| CN-101222922-B | Diarylhydantoin compounds | UNIV CALIFORNIA | 2012-04-18 | — | — | CN | disclosed |
| CN-101222922-B | Diarylhydantoin compounds | UNIV CALIFORNIA | 2012-04-18 | — | — | CN | disclosed |
| CN-101222922-B | Diarylhydantoin compounds | UNIV CALIFORNIA | 2012-04-18 | — | — | CN | disclosed |
| CN-102421291-A | Specific diarylhydantoin and diarylthiohydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS INC | 2012-04-18 | — | — | CN | disclosed |
| EP-2416657-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS FOR USE THEREOF | Medivation Prostate Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| EP-2416657-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS FOR USE THEREOF | Medivation Prostate Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20120035231-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS LLC | 2012-02-09 | — | — | US | disclosed |
| US-20120035231-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS LLC | 2012-02-09 | — | — | US | disclosed |
| US-8110594-B2 | Diarylthiohydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-07 | — | — | US | disclosed |
| EP-1893196-B1 | DIARYLHYDANTOIN COMPOUND | UNIV CALIFORNIA (US) | 2012-01-18 | — | — | EP | disclosed |
| EP-1893196-B1 | DIARYLHYDANTOIN COMPOUND | UNIV CALIFORNIA (US) | 2012-01-18 | — | — | EP | disclosed |
| EP-2400847-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | Medivation Prostate Therapeutics, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2400847-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | Medivation Prostate Therapeutics, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2397469-A1 | Diarylhydantoin compounds | The Regents Of the University of California (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-2397469-A1 | Diarylhydantoin compounds | The Regents Of the University of California (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-2397469-A1 | Diarylhydantoin compounds | The Regents Of the University of California (US) | 2011-12-21 | — | — | EP | disclosed |
| WO-2011106570-A1 | PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011106570-A1 | PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
| US-20110152348-A1 | METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS | ENZON PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2011029537-A1 | SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-17 | — | — | WO | disclosed |
| WO-2010118354-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS FOR USE THEREOF | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118354-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS FOR USE THEREOF | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010099238-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010099238-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| EP-2220050-A2 | DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | The Regents Of The University Of California (US) | 2010-08-25 | — | — | EP | disclosed |
| EP-2220050-A2 | DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | The Regents Of The University Of California (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20100210665-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210665-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100172975-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100172975-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-08 | — | — | US | disclosed |
| US-7709517-B2 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709517-B2 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709517-B2 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-04 | — | — | US | disclosed |
| CN-101460467-A | Diarylthiohydantoin compounds | UNIV CALIFORNIA (US) | 2009-06-17 | — | — | CN | disclosed |
| WO-2009055053-A3 | DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | UNIV CALIFORNIA (US) | 2009-06-11 | — | — | WO | disclosed |
| US-20090111864-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-30 | — | — | US | disclosed |
| US-20090111864-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-30 | — | — | US | disclosed |
| WO-2009055053-A2 | DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009055053-A2 | DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-30 | — | — | WO | disclosed |
| EP-1893196-A4 | DIARYLHYDANTOIN COMPOUNDS | UNIV CALIFORNIA (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-1893196-A4 | DIARYLHYDANTOIN COMPOUNDS | UNIV CALIFORNIA (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-2013187-A2 | DIARYLTHIOHYDANTOIN COMPOUNDS | The Regents of the University of California (US) | 2009-01-14 | — | — | EP | disclosed |
| CN-101222922-A | Diarylhydantoin compounds | UNIV CALIFORNIA (US) | 2008-07-16 | — | — | CN | disclosed |
| CN-101222922-A | Diarylhydantoin compounds | UNIV CALIFORNIA (US) | 2008-07-16 | — | — | CN | disclosed |
| CN-101222922-A | Diarylhydantoin compounds | UNIV CALIFORNIA (US) | 2008-07-16 | — | — | CN | disclosed |
| US-20080139634-A2 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; androgen receptor antagonists with minimal agonist activity | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2007127010-A9 | DIARYLTHIOHYDANTOIN COMPOUNDS | UNIV CALIFORNIA (US) | 2008-05-22 | — | — | WO | disclosed |
| EP-1893196-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1893196-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007129184-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF PHENYTOIN SODIUM | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007127010-A2 | DIARYLTHIOHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070254933-A1 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; selective androgen receptor modulators; non-steroidal, non-toxic, and tissue selective | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006124118-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006124118-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-1998034610-A1 | COMPOSITION FOR IMPROVING HAIR REGROWTH AND METHOD OF USE | GROTON ROBERT B (US) | 1998-08-13 | — | — | WO | disclosed |
| EP-0232311-B1 | TOPICAL COMPOSITION AND METHOD FOR STIMULATING HAIR GROWTH | PROCTOR, Peter H. (US) | 1993-05-12 | — | — | EP | disclosed |
| EP-0192660-B1 | ABSORPTION ENHANCING AGENTS | SURVIVAL TECHNOLOGY, INC. (US) | 1992-11-19 | — | — | EP | disclosed |
| WO-1991015235-A1 | t-PA ENHANCER PROFILE | SURVIVAL TECHNOLOGY, INC. (US) | 1991-10-17 | — | — | WO | disclosed |
| US-5002930-A | Hydroxyamine, Alkylamine, Hydroxyalkylamine | SURVIVAL TECHNOLOGY, INC. (US) | 1991-03-26 | — | — | US | disclosed |
| EP-0383092-A2 | Chromogenic merocyanine enzyme substrates | Bayer Corporation (US) | 1990-08-22 | — | — | EP | disclosed |
| US-RE32919-E | TISSUE-TYPE PLASMINOGEN ACTIVATOR | SURVIVAL TECHNOLOGY, INC. (US) | 1989-05-09 | — | — | US | disclosed |
| EP-0214281-A4 | PROTEIN ABSORPTION ENHANCING AGENTS. | SURVIVAL TECHNOLOGY (US) | 1989-03-16 | — | — | EP | disclosed |
| US-4772585-A | Protein thrombolytic agent with absorption enhancing agent | SURVIVAL TECHNOLOGY, INC. (US) | 1988-09-20 | — | — | US | disclosed |
| US-4661469-A | HYDROXYLAMINE, HYDROXYLAMINE HYDROCHLORIDE DISASSOCIATING AGENT | SURVIVAL TECHNOLOGY, INC. (US) | 1987-04-28 | — | — | US | disclosed |
| US-4656034-A | PREVENTING CYTOLYSIS | SURVIVAL TECHNOLOGY, INC. (US) | 1987-04-07 | — | — | US | disclosed |
| EP-0214281-A1 | PROTEIN ABSORPTION ENHANCING AGENTS. | SURVIVAL TECHNOLOGY (US) | 1987-03-18 | — | — | EP | disclosed |
| EP-0191814-A4 | PROTEIN ABSORPTION ENHANCING AGENTS. | SURVIVAL TECHNOLOGY (US) | 1987-03-16 | — | — | EP | disclosed |
| WO-1986005095-A1 | t-PA COMPOSITION AND METHOD OF GETTING INTO BLOOD STREAM | SURVIVAL TECHNOLOGY, INC. (US) | 1986-09-12 | — | — | WO | disclosed |
| WO-1986005096-A1 | PROTEIN ABSORPTION ENHANCING AGENTS | SURVIVAL TECHNOLOGY, INC. (US) | 1986-09-12 | — | — | WO | disclosed |
| EP-0191814-A1 | PROTEIN ABSORPTION ENHANCING AGENTS. | SURVIVAL TECHNOLOGY (US) | 1986-08-27 | — | — | EP | disclosed |
| EP-0191056-A1 | t-PA COMPOSITION AND METHOD OF GETTING INTO BLOOD STREAM | SURVIVAL TECHNOLOGY, INC. (US) | 1986-08-20 | — | — | EP | disclosed |
| WO-1986001104-A1 | t-PA COMPOSITION AND METHOD OF GETTING INTO BLOOD STREAM | SURVIVAL TECHNOLOGY, INC. (US) | 1986-02-27 | — | — | WO | disclosed |
| WO-1986001109-A1 | PROTEIN ABSORPTION ENHANCING AGENTS | SURVIVAL TECHNOLOGY, INC. (US) | 1986-02-27 | — | — | WO | disclosed |
| US-4514382-A | IMIDAZOLE DERIVATIVE | COLGATE-PALMOLIVE COMPANY (US) | 1985-04-30 | — | — | US | disclosed |
| US-4514382-A | IMIDAZOLE DERIVATIVE | COLGATE-PALMOLIVE COMPANY (US) | 1985-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152348-A1 | METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS | AR, ESRRB, ESRRA | MMP2 3084/4885MMP9 3476/4885MMP3 1559/4885 |
| US-20240132452-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | MMP2 1767/4885MMP9 1537/4885MMP3 755/4885 |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | MMP2 3270/4885MMP9 4169/4885MMP3 3978/4885 |
| US-20120295944-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | CDK4, CCNH, VHL | MMP2 3609/4885MMP9 3503/4885MMP3 1713/4885 |
| US-20120184580-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS OF USE THEREOF | AR, BRDT, AADAC | MMP2 3236/4885MMP9 4034/4885MMP3 2464/4885 |
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | MMP2 3400/4885MMP9 4220/4885MMP3 2649/4885 |
| US-20080139634-A2 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; androgen receptor antagonists with minimal agonist activity | AR, LHCGR, KLK3 | MMP2 3134/4885MMP9 3401/4885MMP3 1977/4885 |
| US-20120251551-A1 | Substituted (Heteroarylmethyl)thiohydantoins | TPMT, BPHL, VHL | MMP2 1913/4885MMP9 2106/4885MMP3 1377/4885 |
| US-20170313662-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | KLK4, KLK5, KLK1 | MMP2 1014/4885MMP9 1573/4885MMP3 1687/4885 |
| US-20070254933-A1 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; selective androgen receptor modulators; non-steroidal, non-toxic, and tissue selective | AR, NR5A1, SHBG | MMP2 2664/4885MMP9 2435/4885MMP3 1222/4885 |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | MMP2 4602/4885MMP9 4688/4885MMP3 4575/4885 |
| US-20190127332-A1 | PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | KLK4, KLK5, KLK1 | MMP2 937/4885MMP9 1600/4885MMP3 1607/4885 |
| US-20180086718-A1 | Diarylhydantoin Compounds | BPHL, AR, SHBG | MMP2 1767/4885MMP9 1537/4885MMP3 755/4885 |
| US-20130331421-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | BPHL, PARK7, APP | MMP2 2313/4885MMP9 1862/4885MMP3 1796/4885 |
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | MMP2 3658/4885MMP9 4168/4885MMP3 3440/4885 |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | AR, BRDT, GNRHR | MMP2 3246/4885MMP9 2043/4885MMP3 1851/4885 |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | MMP2 3658/4885MMP9 4168/4885MMP3 3440/4885 |
| US-20140031409-A1 | METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS | AR, ESRRB, ESRRA | MMP2 3084/4885MMP9 3476/4885MMP3 1559/4885 |
| US-20210054017-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | GNE, FUT6, GALNT13 | MMP2 2794/4885MMP9 4209/4885MMP3 3591/4885 |
| US-10626091-B2 | Process for the preparation of enzalutamide | KLK4, KLK5, KLK1 | MMP2 937/4885MMP9 1600/4885MMP3 1607/4885 |
| US-20100172975-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | CDK4, CCNH, VHL | MMP2 3609/4885MMP9 3503/4885MMP3 1713/4885 |
| US-20130289085-A1 | HISTONE DEACETYLASE (HDAC) INHIBITORS TARGETING PROSTATE TUMORS AND METHODS OF MAKING AND USING THEREOF | HDAC1, HDAC11, HDAC3 | MMP2 442/4885MMP9 655/4885MMP3 260/4885 |
| US-20150065546-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, ACP3, AR | MMP2 989/4885MMP9 1009/4885MMP3 420/4885 |
| US-20130190507-A1 | PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | BPHL, PTMS, DHPS | MMP2 2752/4885MMP9 2816/4885MMP3 2467/4885 |
| US-20190210974-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | MMP2 1767/4885MMP9 1537/4885MMP3 755/4885 |
| US-20180245084-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | SI, FABP2, GNE | MMP2 1435/4885MMP9 2304/4885MMP3 2543/4885 |
| US-10646575-B2 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | MMP2 4602/4885MMP9 4688/4885MMP3 4575/4885 |
| US-20190262315-A1 | Treatment of Breast Cancer | BRCA1, TP53, TUBB6 | MMP2 1614/4885MMP9 2690/4885MMP3 880/4885 |
| US-11992531-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | MMP2 3400/4885MMP9 4220/4885MMP3 2649/4885 |
| US-10570169-B2 | Conjugated antisense compounds and their use | GNE, GALNT1, GALNT6 | MMP2 2480/4885MMP9 3846/4885MMP3 3123/4885 |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | MMP2 3658/4885MMP9 4168/4885MMP3 3440/4885 |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | MMP2 4602/4885MMP9 4688/4885MMP3 4575/4885 |
| US-20120035231-A1 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS | BPHL, PARK7, APP | MMP2 2313/4885MMP9 1862/4885MMP3 1796/4885 |
| US-20170158643-A1 | PROCESS FOR PREPARATION OF ANDROGEN RECEPTOR ANTAGONIST | AR, AVPR2, AVPR1A | MMP2 2239/4885MMP9 3077/4885MMP3 1117/4885 |
| US-20170087132-A1 | Treatment of Breast Cancer | BRCA1, MKI67, BAX | MMP2 125/4885MMP9 617/4885MMP3 412/4885 |
| US-20230095223-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | MMP2 3658/4885MMP9 4168/4885MMP3 3440/4885 |
| US-20200157548-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | SI, FABP2, GNE | MMP2 1435/4885MMP9 2304/4885MMP3 2543/4885 |
| US-20200079741-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | MMP2 1767/4885MMP9 1537/4885MMP3 755/4885 |
| US-10131636-B2 | Process for the preparation of Enzalutamide | KLK4, KLK5, KLK1 | MMP2 937/4885MMP9 1600/4885MMP3 1607/4885 |
| US-20150112082-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | MMP2 1767/4885MMP9 1537/4885MMP3 755/4885 |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | GCGR, STUB1, GID4 | MMP2 3664/4885MMP9 4300/4885MMP3 3500/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | MMP2 2558/4885MMP9 2331/4885MMP3 2404/4885 |
| US-20190076540-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | MMP2 3658/4885MMP9 4168/4885MMP3 3440/4885 |
| US-20140296312-A1 | TREATMENT OF BREAST CANCER | BRCA1, BAX, BAD | MMP2 131/4885MMP9 623/4885MMP3 422/4885 |
| US-20090111864-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, ACP3, AR | MMP2 989/4885MMP9 1009/4885MMP3 420/4885 |
| US-20120190718-A1 | DIARYLTHIOHYDANTOIN COMPOUNDS | AR, SHBG, PTMS | MMP2 3208/4885MMP9 2853/4885MMP3 1700/4885 |
| US-20190076541-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | MMP2 4602/4885MMP9 4688/4885MMP3 4575/4885 |
| US-20130034501-A1 | DIARYLHYDANTOIN COMPOUNDS | FAP, LEF1, LPXN | MMP2 794/4885MMP9 795/4885MMP3 217/4885 |
| US-10111861-B2 | Treatment of breast cancer | BRCA1, MKI67, BAX | MMP2 125/4885MMP9 617/4885MMP3 412/4885 |
| US-20170145424-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | SI, FABP2, GNE | MMP2 1435/4885MMP9 2304/4885MMP3 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.